Skip to main content
Dark area showing tumor against blue background.

TheraSphere™ Y-90 Glass Microspheres

Referring physicians

Proven tumor control

TheraSphere is the first and only FDA approved transarterial radiation therapy for hepatocellular carcinoma (HCC), delivering maximum damage to the tumor, sparing healthy tissue, and preserving treatment options.


How TheraSphere works

TheraSphere is a treatment consisting of millions of tiny glass beads — each thinner than a strand of hair — containing radioactive Yttrium-90. An Interventional Radiologist administers TheraSphere through a microcatheter typically placed in the femoral artery. Each glass bead delivers a highly concentrated dose of radiation that targets the tumor via the hepatic artery.

Progression of TheraSphere treatment of HCC, with tumor becoming smaller.

Radiation directly targets the tumor with minimal impact to the surrounding healthy tissue.


Unprecedented predictability

Studied across a wide range of BCLC stages, TheraSphere is a versatile, data-backed treatment with proven clinical results.

100%

Tumor response in eligible patients1

93%

Overall survival rate at 3 years in patients with transplant or resection1

88%

Demonstrated rate of best response1

Stay connected

Receive the latest advances on TheraSphere, clinical data updates, and how TheraSphere can help your patients.


Preserve HCC treatment options

Early treatment with TheraSphere allows you to maximize your chances for tumor response. Easily delivered through a minimally invasive outpatient procedure, TheraSphere is well-tolerated by patients with minimal side effects. In combination with other therapies, TheraSphere widens the field of treatment possibilities – to ultimately improve patient outcomes.

Checklist icon.

Studied across all BCLC stages

Scalpel cutting icon.

Minimally invasive outpatient procedure3

Target icon in liver.

Maintains patient eligibility for future treatment


Hear Nicole’s story

TheraSphere is the only Y-90 treatment indicated for HCC liver cancer treatment that delivers an optimal, high-potency, personalized dose of radiation for patients, like Nicole.

Location icon.

Treatment center finder

Instantly locate treatment centers administering TheraSphere near you for your HCC patients.

Have your questions answered

Speak with a field representative to learn more about the clinical benefits and possibilities that TheraSphere offers you and your patients.

Information icon.

Resource center

TheraSphere can be an instrumental component to your multi-disciplinary care plan. Be sure to view our resource center to download data sheets, see more product information, and more.

References

  1. Salem R et al. Hepatology 2018; 68(4): 1429-40R
  2. Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819.
  3. Gabr, A., Kulik, L., Mouli, S., Riaz, A., Ali, R., Desai, K., Mora, R.A., Ganger, D., Maddur, H., Flamm, S., Boike, J., Moore, C., Thornburg, B., Alasadi, A., Baker, T., Borja‐Cacho, D., Katariya, N., Ladner, D.P., Caicedo, J.C., Lewandowski, R.J. and Salem, R. (2020), Liver Transplantation Following Yttrium‐90 Radioembolization: 15‐year Experience in 207‐Patient Cohort. Hepatology. Accepted Author Manuscript. doi:10.1002/hep.31318 >=30% hepatic reserve. 

TheraSphere is a registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd., a wholly owned subsidiary of Boston Scientific Corporation.